Y of Pennsylvania, provided guidance with the scanning electron microscopy applications. Author details 1 Thoracic and Cardiovascular Surgery, Sanger Heart Vascular Institute, Carolinas Healthcare Method, Charlotte, NC, USA. 2Internal Medicine, Perlman School of Medicine, University of Pennsylvania Healthcare Center, Philadelphia, PA, USA. 3Pathology and Laboratory Medicine, Perlman College of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA, USA. 4Materials Science Engineering, College of Engineering Applied Science, University of Pennsylvania, Philadelphia, PA, USA. Received: 31 March 2014 Accepted: 10 June 2014 Published: 16 JuneReferences 1. Gheorghiade M, Bonow RO: Chronic heart failure inside the Usa: a manifestation of coronary artery disease. Circulation 1998, 97:28289. two. Frazier OH, Myers TJ: Surgical therapy for serious heart failure. Curr Probl Cardiol 1998, 23:72168. 3. Delgado HD, Rao V, Ross JR, Verma S, Smedira N: Mechanical circulatory assistance (State of Art). Circulation 2002, 106:2046050. 4. Siegenthaler PM, Martin J, Loo A, Doenst T, Bothe W, Beyersdorf F: Implantation on the permanent jarvik-2000 left ventricular help device. JACC 2002, 39:1764772. five. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Extended JW, Ascheim DD, Tierney AR, Levitan RG, Levitan RG, Watson JT, Ronan NS, Meier P: Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001, 345:1435443. 6. Schmia MC, Gumpert AM, Kock WJ: Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther 2014, 14:18395. 7. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, Hadri L, Yoneyama R, Hoshino K, Takewa Y, Sakata S, Peluso R, Zsebo K, Gwathmey JK, Tardif JC, Tanguay JF, Hajjar RJ: Reversal of cardiac dysfunction following long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008, 51(11):1112119. eight. Rengo G, Lymperopoulous A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, Koch WJ: Myocardial adeno-associated serotype six BARKct gene therapy improves cardiac function and normalizes the neurhormonal axis in chronic heart failure. Circulation 2009, 119(1):898. 9. Giacca M, Zacchigna S: VEGF gene therapy:therapeutic angiogenesis in the clinic and beyond. Gene Ther 2012, 19(6):62229. 10. Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, Giacca M: Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012, 492(7249):37681. 11. Wang W, Li W, Ma N, Steinhoff G: Non-viral gene delivery methods. Curr Pharm Biotechnology 2013, 14(1):460. 12. Su CH, Wu YJ, Wang HH, Yeh HI: Non-viral gene therapy targeting the cardiovascular system.Alectinib Am J Physiol Heart Circ 2012, 303(6):62938.Modakafusp alfa 13.PMID:23381626 Katz MG, Swain JD, Tomasulo CE, Sumaroka M, Fargnoli A, Bridges CR: Existing Methods for Myocardial Gene Delivery. J Mol Cell Cardiol 2011, 50(5):76676. Epub 2010 Sep 15. 14. Katz MG, Fargnoli AS, Williams RD, Bridges CR: The road ahead: functioning towards helpful clinical translation of myocardial gene therapies. Ther Deliv 2014, 5(1):391. doi: 10.4155/tde.13.134. 15. Logeart D, Hatem SN, Heimburger M, Le Roux A, Michel JB, Mercadier JJ: The best way to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures Hum Gene Ther 2001, 12:1601610. 16. Katz MG, Fargnoli AS, Williams RD, Bridges CR: Gene therapy for enhancing viral and nonviral vectors for cardiac ailments: Curr.
